Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RA drug LFD-200 enters early human testing

NCT ID NCT07207954

Recruiting now Symptom relief Sponsor: Lifordi Immunotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called LFD-200 in healthy volunteers and people with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body processes the drug. Researchers will give single or multiple doses and watch for side effects. This is a first step to see if LFD-200 might help control RA symptoms in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • "ARENSIA EXPLORATORY MEDICINE" LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials

    RECRUITING

    Kyiv, 1135, Ukraine

  • Arensia Exploratory Medicine LLC

    RECRUITING

    Tbilisi, 112, Georgia

  • Centrum Medyczne Reuma Park

    NOT_YET_RECRUITING

    Warsaw, 02-691, Poland

  • Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M.

    RECRUITING

    Chisinau, MD2025, Moldova

  • MICS Centrum Medyczne Torun - MICS - PPDS

    NOT_YET_RECRUITING

    Torun, 87-100, Poland

  • Nucleus Network

    RECRUITING

    Melbourne, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.